Free Trial
→ URGENT: Someone's Moving Gold Out of London... (From Golden Portfolio) (Ad) Buy KRYS Stock  Free KRYS Stock Alerts

Krystal Biotech (KRYS) Financials

Krystal Biotech logo
$123.36 -3.09 (-2.44%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$123.41 +0.05 (+0.04%)
As of 05/28/2025 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Krystal Biotech

Annual Income Statements for Krystal Biotech

This table shows Krystal Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Net Income / (Loss) Attributable to Common Shareholders		 89 11 -140 -70 -32 -19 -11 -7.92 -1.15
Consolidated Net Income / (Loss)		 89 11 -140 -70 -32 -19 -11 -7.92 -1.15
Net Income / (Loss) Continuing Operations		 89 11 -140 -70 -32 -19 -11 -7.92 -1.15
Total Pre-Tax Income 		95 13 -140 -70 -32 -19 -11 -7.92 -1.15
Total Operating Income		 66 -110 -145 -68 -33 -22 -12 -4.77 -1.14
Total Gross Profit		 270 48 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 291 51 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 291 51 0.00 0.00 - - - - -
Total Cost of Revenue		 20 3.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cost of Revenue		 20 3.09 - 0.00 - - - - -
Total Operating Expenses		 205 157 145 68 33 22 12 4.77 1.14
Selling, General & Admin Expense		 114 98 78 40 15 6.47 4.16 1.56 0.40
Research & Development Expense		 54 46 42 28 18 16 7.76 3.21 0.74
Other Special Charges / (Income)		 38 13 25 0.00 0.00 - - - -
Total Other Income / (Expense), net		 30 123 5.22 -1.30 0.83 2.99 1.03 -3.15 -0.01
Interest & Investment Income		 30 23 5.22 0.20 - - - - -
Other Income / (Expense), net		 0.00 100 0.00 0.00 0.83 - 1.03 -3.15 -0.01
Income Tax Expense		 6.20 1.97 0.00 0.00 - - - - -
Basic Earnings per Share		 $3.12 $0.40 ($5.49) ($3.13) ($1.71) ($1.20) ($0.97) ($1.48) ($1.31)
Weighted Average Basic Shares Outstanding		 28.59M 27.15M 25.49M 22.20M 18.79M 15.90M 11.20M 10.31M 877.49K
Diluted Earnings per Share		 $3.00 $0.39 ($5.49) ($3.13) ($1.71) ($1.20) ($0.97) ($1.48) ($1.31)
Weighted Average Diluted Shares Outstanding		 29.74M 27.75M 25.49M 22.20M 18.79M 15.90M 11.20M 10.31M 877.49K
Weighted Average Basic & Diluted Shares Outstanding		 28.81M 28.29M - 25.76M 18.79M 15.90M 11.20M 5.36M 877.49K

Quarterly Income Statements for Krystal Biotech

This table shows Krystal Biotech's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 36 45 27 16 0.93 8.69 81 -33 -45 -32 -30
Consolidated Net Income / (Loss)		 36 45 27 16 0.93 8.69 81 -33 -45 -32 -30
Net Income / (Loss) Continuing Operations		 36 45 27 16 0.93 8.69 81 -33 -45 -32 -30
Total Pre-Tax Income 		44 49 30 16 0.93 11 81 -33 -45 -32 -30
Total Operating Income		 36 41 22 8.57 -6.68 3.14 -26 -38 -49 -35 -31
Total Gross Profit		 83 86 77 64 43 39 8.56 0.00 0.00 - 0.00
Total Revenue		 88 91 84 70 45 42 8.56 0.00 0.00 - 0.00
Operating Revenue		 88 91 84 70 45 42 8.56 0.00 0.00 - 0.00
Total Cost of Revenue		 5.03 4.95 6.68 6.01 2.42 3.09 0.00 0.00 0.00 - 0.00
Operating Cost of Revenue		 5.03 4.95 6.68 6.01 2.42 - - 0.00 0.00 - 0.00
Total Operating Expenses		 47 45 55 56 50 36 34 38 49 35 31
Selling, General & Admin Expense		 33 31 29 28 26 25 24 26 24 24 20
Research & Development Expense		 14 14 14 16 11 11 11 12 12 11 12
Other Special Charges / (Income)		 0.00 - 13 13 13 - 0.00 0.00 13 - 0.00
Total Other Income / (Expense), net		 7.42 7.23 7.34 7.48 7.62 7.52 107 4.84 3.53 2.98 1.60
Interest & Investment Income		 7.42 - 7.34 - - - 6.74 4.84 - - 1.60
Income Tax Expense		 7.86 - 2.59 0.48 - - 0.00 0.00 - - -
Basic Earnings per Share		 $1.24 $1.60 $0.95 $0.54 $0.03 $0.53 $2.88 ($1.25) ($1.76) ($1.23) ($1.17)
Weighted Average Basic Shares Outstanding		 28.82M 28.59M 28.72M 28.60M 28.30M 27.15M 28.04M 26.66M 25.71M 25.49M 25.62M
Diluted Earnings per Share		 $1.20 $1.53 $0.91 $0.53 $0.03 $0.61 $2.79 ($1.25) ($1.76) ($1.23) ($1.17)
Weighted Average Diluted Shares Outstanding		 29.87M 29.74M 29.90M 29.64M 29.29M 27.75M 28.89M 26.66M 25.71M 25.49M 25.62M
Weighted Average Basic & Diluted Shares Outstanding		 28.90M 28.81M 28.76M 28.73M 28.56M 28.29M 28.21M - 27.99M 0.00 25.75M

Annual Cash Flow Statements for Krystal Biotech

This table details how cash moves in and out of Krystal Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Net Change in Cash & Equivalents		 -13 196 -179 73 81 84 54 48 1.92
Net Cash From Operating Activities		 123 -89 -101 -48 -26 -19 -9.45 -3.89 -1.31
Net Cash From Continuing Operating Activities		 123 -89 -101 -48 -26 -19 -9.45 -3.89 -1.31
Net Income / (Loss) Continuing Operations		 89 11 -140 -70 -32 -19 -11 -7.92 -1.15
Consolidated Net Income / (Loss)		 89 11 -140 -70 -32 -19 -11 -7.92 -1.15
Depreciation Expense		 5.97 5.01 2.64 1.85 1.85 1.09 0.14 0.02 0.00
Amortization Expense		 0.75 -1.28 0.74 0.92 - - - - -
Non-Cash Adjustments To Reconcile Net Income		 73 -65 33 17 3.31 1.31 0.79 3.51 0.04
Changes in Operating Assets and Liabilities, net		 -45 -38 2.66 2.05 0.93 -2.00 0.51 0.50 -0.20
Net Cash From Investing Activities		 -163 83 -114 -227 -11 -4.99 -10 -0.21 -0.02
Net Cash From Continuing Investing Activities		 -163 83 -114 -227 -11 -4.99 -10 -0.21 -0.02
Purchase of Property, Plant & Equipment		 -4.24 -12 -53 -68 -15 -6.40 -2.23 -0.21 -0.02
Purchase of Investments		 -458 -509 -319 -190 -3.21 -9.09 -8.09 - -
Divestitures		 0.00 100 0.00 0.00 - - - - -
Sale and/or Maturity of Investments		 299 503 258 32 6.87 11 - - -
Net Cash From Financing Activities		 27 203 35 348 118 108 74 52 3.25
Net Cash From Continuing Financing Activities		 27 203 35 348 118 108 74 52 3.25
Issuance of Common Equity		 0.00 160 29 356 118 108 74 42 0.10
Other Financing Activities, net		 27 43 6.36 -7.96 0.00 - - - -
Effect of Exchange Rate Changes		 -0.46 -0.16 -0.04 0.00 0.00 - - - -
Cash Income Taxes Paid		 5.67 0.00 0.00 - - - - - -

Quarterly Cash Flow Statements for Krystal Biotech

This table details how cash moves in and out of Krystal Biotech's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -36 -29 28 -13 0.68 -15 97 135 -21 -25 -32
Net Cash From Operating Activities		 31 53 59 -4.17 16 -7.23 -21 -34 -26 -22 -20
Net Cash From Continuing Operating Activities		 31 53 59 -4.17 16 -7.23 -21 -34 -26 -23 -20
Net Income / (Loss) Continuing Operations		 36 45 27 16 0.93 8.69 81 -33 -45 -32 -30
Consolidated Net Income / (Loss)		 36 45 27 16 0.93 8.69 81 -33 -45 -32 -30
Depreciation Expense		 1.41 1.36 1.34 1.84 1.43 1.52 1.14 1.26 1.09 -0.32 0.98
Amortization Expense		 0.22 0.19 0.19 0.19 0.18 -1.95 0.23 0.22 0.22 - -
Non-Cash Adjustments To Reconcile Net Income		 -20 12 18 24 20 10 -94 -3.19 22 9.24 8.84
Changes in Operating Assets and Liabilities, net		 13 -5.73 13 -45 -6.44 -26 -9.62 0.73 -3.69 -0.58 0.33
Net Cash From Investing Activities		 -55 -84 -34 -19 -26 -10 105 -16 3.56 -5.21 -15
Net Cash From Continuing Investing Activities		 -55 -84 -34 -19 -26 -10 105 -16 3.56 -5.21 -15
Purchase of Property, Plant & Equipment		 -6.20 -0.80 -1.05 -1.13 -1.26 -1.85 -1.78 -2.79 -5.38 -5.22 -14
Purchase of Investments		 -138 -143 -113 -113 -88 -83 -106 -174 -146 -104 -67
Sale of Property, Plant & Equipment		 0.44 - - - - - - - - - -
Sale and/or Maturity of Investments		 89 60 79 95 64 75 113 161 155 104 67
Net Cash From Financing Activities		 -12 2.43 3.37 11 11 2.62 13 185 1.47 3.07 2.12
Net Cash From Continuing Financing Activities		 -12 2.43 3.37 11 11 2.62 13 185 1.47 3.07 2.12
Other Financing Activities, net		 -12 2.43 3.37 11 11 2.61 14 25 1.47 7.01 -
Effect of Exchange Rate Changes		 0.17 -0.59 0.29 -0.34 0.19 -0.14 0.01 - - -0.04 -
Cash Income Taxes Paid		 0.40 0.52 3.15 - - - - - - - -

Annual Balance Sheets for Krystal Biotech

This table presents Krystal Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2022 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Total Assets		 1,056 818 558 558 311 209 116 50 2.18
Total Current Assets		 742 588 384 384 275 196 113 50 2.17
Cash & Equivalents		 345 358 162 162 268 188 104 50 1.92
Short-Term Investments		 253 174 217 217 2.99 6.17 8.09 0.00 -
Accounts Receivable		 105 42 0.00 - - - - - -
Inventories, net		 27 6.99 0.00 - - - - - -
Prepaid Expenses		 13 6.71 4.61 4.61 3.80 2.20 0.89 0.32 0.25
Plant, Property, & Equipment, net		 155 161 162 162 31 8.48 3.01 0.20 0.01
Total Noncurrent Assets		 159 69 13 13 4.91 4.67 0.45 0.00 0.00
Long-Term Investments		 152 62 4.62 4.62 0.00 0.50 - - -
Other Noncurrent Operating Assets		 6.51 7.29 8.37 8.37 4.91 4.17 0.45 - -
Total Liabilities & Shareholders' Equity		 1,056 818 558 558 311 209 116 50 2.18
Total Liabilities		 109 40 36 36 19 6.11 2.89 0.64 1.89
Total Current Liabilities		 102 33 29 29 15 3.33 2.60 0.64 0.04
Accounts Payable		 64 26 27 27 2.11 1.02 2.60 0.64 0.04
Accrued Expenses		 37 5.98 - - 5.11 1.83 - - -
Other Current Liabilities		 1.22 1.47 1.56 1.56 8.24 0.48 - - -
Total Noncurrent Liabilities		 7.46 6.62 7.37 7.37 3.31 2.78 0.29 0.00 1.85
Other Noncurrent Operating Liabilities		 7.46 6.62 7.37 7.37 3.31 2.78 0.29 0.00 -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 946 779 522 522 292 203 113 49 0.29
Total Preferred & Common Equity		 946 779 522 522 292 203 113 49 0.29
Total Common Equity		 946 779 522 522 292 203 113 49 -1.12
Common Stock		 1,127 1,048 804 804 363 242 133 59 0.03
Retained Earnings		 -181 -270 -281 -281 -71 -39 -20 -9.07 -1.15
Accumulated Other Comprehensive Income / (Loss)		 -0.19 0.64 -0.73 -0.73 0.01 0.01 0.00 0.00 -

Quarterly Balance Sheets for Krystal Biotech

This table presents Krystal Biotech's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 12/31/2022
Total Assets		 1,074 982 918 853 790 684 558
Total Current Assets		 767 713 683 602 582 484 384
Cash & Equivalents		 309 374 346 359 373 276 162
Short-Term Investments		 308 214 214 179 189 202 217
Accounts Receivable		 103 97 103 46 9.32 - -
Inventories, net		 30 19 12 11 5.28 - -
Prepaid Expenses		 17 8.96 7.75 6.49 5.47 6.49 4.61
Plant, Property, & Equipment, net		 151 157 159 160 164 164 162
Total Noncurrent Assets		 157 113 76 91 44 36 13
Long-Term Investments		 148 106 69 84 37 28 4.62
Other Noncurrent Operating Assets		 8.08 6.67 6.79 7.04 7.65 7.88 8.37
Total Liabilities & Shareholders' Equity		 1,074 982 918 853 790 684 558
Total Liabilities		 90 96 79 54 34 31 36
Total Current Liabilities		 79 90 72 48 28 24 29
Accounts Payable		 31 59 49 35 26 22 27
Accrued Expenses		 47 30 22 11 - - -
Other Current Liabilities		 1.36 1.29 1.36 1.43 1.50 1.53 1.56
Total Noncurrent Liabilities		 10 6.95 6.91 6.47 6.82 7.01 7.37
Other Noncurrent Operating Liabilities		 10 6.95 6.91 6.47 6.82 7.01 7.37
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 985 886 839 799 756 653 522
Total Preferred & Common Equity		 985 886 839 799 756 653 522
Total Common Equity		 985 886 839 799 756 653 522
Common Stock		 1,129 1,110 1,093 1,068 1,035 1,013 804
Retained Earnings		 -145 -226 -253 -269 -279 -359 -281
Accumulated Other Comprehensive Income / (Loss)		 0.39 1.51 -0.63 -0.30 -0.38 -0.24 -0.73

Annual Metrics And Ratios for Krystal Biotech

This table displays calculated financial ratios and metrics derived from Krystal Biotech's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Growth Metrics		 - - - - - - - - -
Revenue Growth		 473.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 1,307.02% 95.77% -116.49% -116.08% -44.42% -95.30% -36.10% -587.89% 0.00%
EBIT Growth		 775.39% 93.30% -112.66% -112.25% -45.68% -102.78% -37.49% -588.70% 0.00%
NOPAT Growth		 166.04% 8.49% -112.66% -106.90% -49.45% -85.31% -149.71% -317.50% 0.00%
Net Income Growth		 715.58% 107.81% -101.20% -116.28% -68.52% -75.30% -37.49% -588.70% 0.00%
EPS Growth		 669.23% 107.10% -75.40% -83.04% -42.50% -23.71% 34.46% -12.98% 0.00%
Operating Cash Flow Growth		 238.98% 11.70% -109.79% -83.79% -39.56% -97.88% -142.80% -196.72% 0.00%
Free Cash Flow Firm Growth		 135.37% -36.84% 38.55% -370.06% -54.86% -129.00% -229.96% 0.00% 0.00%
Invested Capital Growth		 6.63% 33.28% 0.00% 564.87% 138.46% 496.04% 1,352.14% -154.17% 0.00%
Revenue Q/Q Growth		 20.29% 492.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 124.97% 95.85% -9.53% -20.54% -12.13% -8.59% -26.73% 0.00% 0.00%
EBIT Q/Q Growth		 139.31% 93.41% -9.75% -20.17% -11.94% -9.62% -26.99% 0.00% 0.00%
NOPAT Q/Q Growth		 123.76% 10.00% -9.75% -20.17% -14.84% -9.62% -29.56% 0.00% 0.00%
Net Income Q/Q Growth		 70.24% 136.67% -7.90% -19.65% -18.52% -9.46% -26.99% 0.00% 0.00%
EPS Q/Q Growth		 44.23% 126.90% -5.37% -15.07% -17.12% -0.84% -76.36% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 94.84% 14.53% -1.44% -36.72% -4.09% -22.90% -17.27% -48.25% 0.00%
Free Cash Flow Firm Q/Q Growth		 817.93% -13.78% 45.10% -135.21% -13.40% -22.56% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 2.67% 17.27% 0.00% 201.56% 35.60% 96.76% 73,350.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 93.09% 93.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 24.92% -11.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 22.61% -216.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 22.61% -19.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 30.69% 21.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 93.50% 84.76% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 145.15% -132.59% 96.40% 101.90% 100.00% 86.45% 100.00% 100.00% 100.00%
Effective Tax Rate		 6.50% 15.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 32.22% -57.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 28.09% -78.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -21.89% 59.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 10.34% 1.68% -26.80% -17.09% -13.00% -12.08% -13.39% -31.83% -397.92%
Cash Return on Invested Capital (CROIC)		 25.80% -86.13% -73.42% -207.72% -238.14% -445.69% -677.35% 0.00% 0.00%
Operating Return on Assets (OROA)		 7.01% -1.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 9.51% 1.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 10.34% 1.68% -26.80% -17.09% -13.00% -12.08% -13.39% -30.93% 1,538.00%
Return on Equity Simple (ROE_SIMPLE)		 9.42% 1.40% -26.80% -13.32% -11.01% -9.41% -9.62% -16.01% -397.92%
Net Operating Profit after Tax (NOPAT)		 61 -93 -102 -48 -23 -15 -8.34 -3.34 -0.80
NOPAT Margin		 21.14% -183.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 4.13% 21.26% -9.99% -6.65% -3.90% -2.37% -3.16% -18.44% -479.32%
Return On Investment Capital (ROIC_SIMPLE)		 6.49% -11.95% -19.46% - - - - - -
Cost of Revenue to Revenue		 6.91% 6.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 39.13% 194.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 18.44% 91.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 70.48% 310.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 66 -9.73 -145 -68 -32 -22 -11 -7.92 -1.15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 72 -6.00 -142 -66 -30 -21 -11 -7.90 -1.15
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 4.76 4.49 3.91 2.98 4.05 4.72 2.65 2.18 0.00
Price to Tangible Book Value (P/TBV)		 4.76 4.49 3.91 2.98 4.05 4.72 2.65 2.18 0.00
Price to Revenue (P/Rev)		 15.51 69.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 50.53 320.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 1.98% 0.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 19.09 15.75 11.96 8.46 43.76 87.54 128.38 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 12.93 57.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 51.87 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 57.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 61.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 30.43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 76.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.38
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.38
Financial Leverage		 -0.78 -0.75 -0.73 -0.80 -0.94 -0.97 -0.99 -1.00 -0.25
Leverage Ratio		 1.09 1.06 1.07 1.07 1.05 1.03 1.02 1.05 7.55
Compound Leverage Factor		 1.58 -1.40 1.03 1.09 1.05 0.89 1.02 1.05 7.55
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 86.44%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 86.44%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 65.95%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -52.39%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.61
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.61
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.30
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.30
Altman Z-Score		 25.67 53.24 32.99 25.42 38.16 94.64 62.84 101.37 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.83% 486.51%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 7.28 17.76 13.30 13.30 17.80 58.88 43.39 77.99 50.44
Quick Ratio		 6.89 17.35 13.14 13.14 17.56 58.22 43.05 77.49 44.72
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 49 -139 -102 -165 -35 -23 -9.92 -3.01 0.00
Operating Cash Flow to CapEx		 2,912.22% -752.64% -189.83% -70.15% -175.73% -292.08% -422.78% -1,852.38% -8,740.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -110.86 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -32.13 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -77.93 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.31 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 3.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 1.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.84 0.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.45 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 92.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 304.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 815.27 3,122.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -418.36 -3,122.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 197 185 138 138 21 8.73 1.47 -0.12 0.22
Invested Capital Turnover		 1.52 0.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 12 46 0.00 118 12 7.27 1.58 -0.33 0.00
Enterprise Value (EV)		 3,756 2,905 1,656 1,172 911 764 188 58 0.00
Market Capitalization		 4,506 3,499 2,040 1,556 1,182 959 300 108 0.00
Book Value per Share		 $32.91 $27.61 $20.28 $23.48 $14.82 $11.72 $7.85 $4.83 ($1.27)
Tangible Book Value per Share		 $32.91 $27.61 $20.28 $23.48 $14.82 $11.72 $7.85 $4.83 ($1.27)
Total Capital		 946 779 522 522 292 203 113 49 2.13
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.84
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.84
Net Debt		 -750 -594 -384 -384 -271 -194 -112 -50 -0.08
Capital Expenditures (CapEx)		 4.24 12 53 68 15 6.40 2.23 0.21 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 43 23 -24 -24 -12 -1.13 -1.71 -0.32 0.20
Debt-free Net Working Capital (DFNWC)		 640 555 355 355 260 193 110 49 2.13
Net Working Capital (NWC)		 640 555 355 355 260 193 110 49 2.13
Net Nonoperating Expense (NNE)		 -28 -104 38 22 9.07 3.63 2.55 4.58 0.35
Net Nonoperating Obligations (NNO)		 -750 -594 -384 -384 -271 -194 -112 -50 -0.07
Total Depreciation and Amortization (D&A)		 6.71 3.73 3.39 2.77 1.85 1.09 0.14 0.02 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 14.64% 44.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 220.32% 1,094.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 220.32% 1,094.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $3.12 $0.40 $0.00 $0.00 ($1.71) ($1.20) ($0.97) ($1.48) ($1.31)
Adjusted Weighted Average Basic Shares Outstanding		 28.59M 27.15M 0.00 0.00 22.19M 17.36M 11.20M 10.31M 877.49K
Adjusted Diluted Earnings per Share		 $3.00 $0.39 $0.00 $0.00 ($1.71) ($1.20) ($0.97) ($1.48) ($1.31)
Adjusted Weighted Average Diluted Shares Outstanding		 29.74M 27.75M 0.00 0.00 22.19M 17.36M 11.20M 10.31M 877.49K
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($1.71) ($1.20) ($0.97) ($1.48) ($1.31)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 28.81M 28.29M 0.00 0.00 18.79M 15.90M 11.20M 5.36M 877.49K
Normalized Net Operating Profit after Tax (NOPAT)		 96 -82 -84 -48 -23 -15 -8.34 -3.34 -0.80
Normalized NOPAT Margin		 33.21% -162.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 32.82% 25.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -45.76 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 -32.03 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -91.56 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -77.83 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Krystal Biotech

This table displays calculated financial ratios and metrics derived from Krystal Biotech's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 94.88% 116.26% 879.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 845.04% 926.93% -68.21% 149.40% 105.35% 107.73% 347.32% -34.79% 3.44% -59.42% -104.96%
EBIT Growth		 641.25% 737.90% -69.69% 142.17% 101.91% 109.02% 335.31% -35.36% 2.79% -58.93% -100.94%
NOPAT Growth		 543.62% 1,219.09% 178.80% 131.21% 80.44% 112.89% -18.07% -32.33% 2.79% -58.93% -100.94%
Net Income Growth		 3,734.01% 423.23% -66.34% 146.88% 102.06% 127.12% 370.51% -18.15% 9.34% -46.99% -91.48%
EPS Growth		 3,900.00% 150.82% -67.38% 142.40% 101.70% 149.59% 338.46% -13.64% 11.56% -29.47% -67.14%
Operating Cash Flow Growth		 94.92% 830.68% 377.29% 87.81% 160.74% 67.61% -7.81% 20.60% -68.82% -6.84% -171.37%
Free Cash Flow Firm Growth		 65.14% 167.87% 69.21% -314.37% 63.80% -76.40% 60.82% 184.42% -13.87% 81.69% -175.96%
Invested Capital Growth		 23.94% 6.63% 21.80% 0.00% 20.25% 33.28% 13.65% 0.00% 82.65% 0.00% 201.56%
Revenue Q/Q Growth		 -3.24% 8.71% 19.29% 55.32% 7.37% 392.55% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 35.82% 16.18% 32.64% 610.98% -54.42% -96.40% 306.10% 23.03% -35.39% -15.15% -12.32%
EBIT Q/Q Growth		 37.63% 17.17% 39.81% 1,621.57% -70.29% -95.76% 294.51% 22.07% -40.42% -10.55% -11.89%
NOPAT Q/Q Growth		 -28.34% 102.03% 146.43% 224.35% -313.07% 112.07% 2.41% 22.07% -40.42% -10.55% -9.38%
Net Income Q/Q Growth		 -21.43% 67.33% 74.59% 1,570.39% -89.28% -89.24% 343.14% 26.68% -41.32% -7.38% -6.20%
EPS Q/Q Growth		 -21.57% 68.13% 71.70% 1,666.67% -95.08% -78.14% 323.20% 28.98% -43.09% -5.13% -6.36%
Operating Cash Flow Q/Q Growth		 -41.39% -10.22% 1,512.12% -126.23% 319.69% 65.93% 37.92% -30.72% -17.14% -13.41% 54.28%
Free Cash Flow Firm Q/Q Growth		 -143.64% 310.84% 93.15% -452.78% 15.02% 4.35% -147.71% 193.35% -314.07% 78.75% -2.79%
Invested Capital Q/Q Growth		 11.49% 2.67% -8.74% 18.65% -4.08% 17.27% 0.00% -100.00% 6.32% 0.00% 14.68%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 94.30% 94.57% 92.03% 91.45% 94.65% 92.66% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 42.88% 30.55% 28.58% 25.70% 5.62% 6.43% 880.93% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 41.02% 45.40% 26.76% 12.19% -14.77% 7.44% -303.80% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 41.02% 28.84% 26.76% 22.83% 2.06% 7.44% 864.97% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 40.52% 49.90% 32.42% 22.15% 2.06% 20.63% 943.75% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 81.96% 93.56% 91.30% 97.03% 100.00% 81.56% 100.00% 100.00% 100.00% 100.81% 100.00%
Interest Burden Percent		 120.51% 184.93% 132.70% 100.00% 100.00% 339.72% 109.11% 87.28% 92.78% 91.44% 94.91%
Effective Tax Rate		 18.04% 0.00% 8.70% 2.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 56.58% 69.19% 33.82% 18.72% -8.74% 2.34% -17.58% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 55.70% 68.58% 32.78% 16.41% -10.09% 1.20% -39.31% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -43.33% -53.42% -25.81% -12.31% 7.84% -0.90% 30.21% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 13.25% 15.77% 8.00% 6.42% -0.90% 1.43% 12.63% 0.00% -22.52% -26.80% -27.88%
Cash Return on Invested Capital (CROIC)		 27.82% 25.80% -3.93% -219.98% -60.08% -86.13% -82.66% 0.00% -146.87% -73.42% -200.87%
Operating Return on Assets (OROA)		 14.19% 8.94% 7.29% 4.14% 0.26% 0.55% 10.97% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 14.02% 15.47% 8.83% 4.01% 0.26% 1.52% 11.97% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 13.25% 15.77% 8.00% 6.42% -0.90% 1.43% 12.63% 0.00% -22.52% -26.80% -27.88%
Return on Equity Simple (ROE_SIMPLE)		 12.59% 0.00% 5.91% 12.63% 7.15% 0.00% -3.94% 0.00% -20.72% 0.00% -24.84%
Net Operating Profit after Tax (NOPAT)		 30 41 20 8.31 -6.68 3.14 -26 -27 -34 -24 -22
NOPAT Margin		 33.62% 45.40% 24.43% 11.83% -14.77% 7.44% -303.80% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.88% 0.61% 1.04% 2.31% 1.35% 1.14% 21.73% 0.00% -2.28% -2.01% -2.10%
Return On Investment Capital (ROIC_SIMPLE)		 3.01% 4.37% - - - 0.40% - - - -4.66% -
Cost of Revenue to Revenue		 5.70% 5.43% 7.97% 8.55% 5.35% 7.34% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 37.11% 34.33% 34.25% 39.31% 57.59% 58.76% 276.96% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 16.17% 14.84% 16.12% 22.17% 24.21% 26.98% 124.23% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 53.27% 49.17% 65.27% 79.26% 109.43% 85.74% 401.19% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 36 26 22 16 0.93 3.14 74 -38 -49 -35 -31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 38 28 24 18 2.54 2.71 75 -37 -48 -35 -30
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.27 4.76 5.90 6.25 6.28 4.49 4.30 0.00 3.16 3.91 3.43
Price to Tangible Book Value (P/TBV)		 5.27 4.76 5.90 6.25 6.28 4.49 4.30 0.00 3.16 3.91 3.43
Price to Revenue (P/Rev)		 15.58 15.51 21.65 31.55 52.31 69.02 379.54 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 41.90 50.53 99.86 49.50 87.80 320.09 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 2.39% 1.98% 1.00% 2.02% 1.14% 0.31% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 20.19 19.09 23.67 21.98 24.84 15.75 16.84 0.00 10.58 11.96 10.15
Enterprise Value to Revenue (EV/Rev)		 13.28 12.93 18.78 27.77 45.82 57.30 309.57 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 38.41 51.87 140.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 40.79 57.17 165.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 45.42 61.15 165.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 31.97 30.43 71.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 80.33 76.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.78 -0.78 -0.79 -0.75 -0.78 -0.75 -0.77 0.00 -0.81 -0.73 -0.80
Leverage Ratio		 1.08 1.09 1.08 1.09 1.06 1.06 1.06 0.00 1.08 1.07 1.09
Compound Leverage Factor		 1.30 2.01 1.43 1.09 1.06 3.60 1.15 0.00 1.00 0.98 1.03
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 35.72 25.54 33.29 40.60 56.16 53.29 57.30 0.00 39.87 33.64 29.51
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.65 7.28 7.97 9.50 12.66 17.76 21.10 0.00 20.25 13.30 13.30
Quick Ratio		 9.06 6.89 7.66 9.23 12.29 17.35 20.72 0.00 19.98 13.14 13.14
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -13 29 -14 -202 -36 -43 -45 94 -101 -24 -115
Operating Cash Flow to CapEx		 536.82% 6,597.13% 5,626.86% -368.52% 1,260.95% -391.55% -1,191.80% -1,225.45% -486.08% -428.00% -140.07%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.35 0.31 0.27 0.18 0.12 0.07 0.01 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 4.45 3.96 4.53 1.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 1.11 1.20 1.53 0.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.14 1.84 1.51 1.05 0.59 0.31 0.05 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.69 0.45 0.43 0.24 0.19 0.12 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 81.95 92.21 80.56 226.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 329.89 304.69 239.17 385.81 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 528.03 815.27 849.77 1,544.55 1,894.82 3,122.02 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -116.19 -418.36 -530.04 -932.06 -1,894.82 -3,122.02 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 219 197 192 210 177 185 157 0.00 147 138 138
Invested Capital Turnover		 1.68 1.52 1.38 1.58 0.59 0.31 0.06 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 42 12 34 210 30 46 19 -121 67 0.00 93
Enterprise Value (EV)		 4,428 3,756 4,536 4,616 4,396 2,905 2,649 0.00 1,557 1,656 1,405
Market Capitalization		 5,194 4,506 5,230 5,244 5,019 3,499 3,247 3,029 2,063 2,040 1,789
Book Value per Share		 $34.18 $32.91 $30.83 $29.37 $28.25 $27.61 $27.00 $0.00 $25.35 $20.28 $20.35
Tangible Book Value per Share		 $34.18 $32.91 $30.83 $29.37 $28.25 $27.61 $27.00 $0.00 $25.35 $20.28 $20.35
Total Capital		 985 946 886 839 799 779 756 0.00 653 522 522
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -765 -750 -694 -629 -622 -594 -599 0.00 -506 -384 -384
Capital Expenditures (CapEx)		 5.77 0.80 1.05 1.13 1.26 1.85 1.78 2.79 5.38 5.22 14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 70 43 35 51 16 23 -7.52 0.00 -17 -24 -24
Debt-free Net Working Capital (DFNWC)		 687 640 624 611 555 555 555 0.00 460 355 355
Net Working Capital (NWC)		 687 640 624 611 555 555 555 0.00 460 355 355
Net Nonoperating Expense (NNE)		 -6.08 -4.10 -6.70 -7.26 -7.62 -5.56 -107 6.58 11 7.71 7.83
Net Nonoperating Obligations (NNO)		 -765 -750 -694 -629 -622 -594 -599 0.00 -506 -384 -384
Total Depreciation and Amortization (D&A)		 1.63 1.56 1.53 2.02 1.61 -0.43 1.37 1.48 1.31 -0.32 0.98
Debt-free, Cash-free Net Working Capital to Revenue		 21.13% 14.64% 14.62% 30.87% 17.09% 44.65% -87.94% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 206.12% 220.32% 258.22% 367.51% 578.08% 1,094.33% 6,481.36% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 206.12% 220.32% 258.22% 367.51% 578.08% 1,094.33% 6,481.36% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.24 $1.60 $0.95 $0.54 $0.03 $0.53 $2.88 $0.00 $0.00 ($1.23) ($1.17)
Adjusted Weighted Average Basic Shares Outstanding		 28.82M 28.59M 28.72M 28.60M 28.30M 27.15M 28.04M 0.00 0.00 25.49M 25.62M
Adjusted Diluted Earnings per Share		 $1.20 $1.53 $0.91 $0.53 $0.03 $0.61 $2.79 $0.00 $0.00 ($1.23) ($1.17)
Adjusted Weighted Average Diluted Shares Outstanding		 29.87M 29.74M 29.90M 29.64M 29.29M 27.75M 28.89M 0.00 0.00 25.49M 25.62M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 28.90M 28.81M 28.76M 28.73M 28.56M 28.29M 28.21M 0.00 0.00 0.00 25.75M
Normalized Net Operating Profit after Tax (NOPAT)		 30 29 32 20 4.07 2.20 -18 -27 -25 -24 -22
Normalized NOPAT Margin		 33.62% 31.78% 38.04% 29.08% 9.00% 5.21% -212.66% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 49.44% 53.34% 35.51% 22.83% 2.06% 25.29% 943.75% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Krystal Biotech's Financials

When does Krystal Biotech's financial year end?

According to the most recent income statement we have on file, Krystal Biotech's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Krystal Biotech's net income changed over the last 8 years?

Krystal Biotech's net income appears to be on a downward trend, with a most recent value of $89.16 million in 2024, falling from -$1.15 million in 2016. The previous period was $10.93 million in 2023. Find out what analysts predict for Krystal Biotech in the coming months.

What is Krystal Biotech's operating income?
Krystal Biotech's total operating income in 2024 was $65.70 million, based on the following breakdown:
  • Total Gross Profit: $270.45 million
  • Total Operating Expenses: $204.76 million
How has Krystal Biotech revenue changed over the last 8 years?

Over the last 8 years, Krystal Biotech's total revenue changed from $0.00 in 2016 to $290.52 million in 2024, a change of 29,051,500,000.0%.

How much debt does Krystal Biotech have?

Krystal Biotech's total liabilities were at $109.46 million at the end of 2024, a 175.6% increase from 2023, and a 5,682.3% increase since 2016.

How much cash does Krystal Biotech have?

In the past 8 years, Krystal Biotech's cash and equivalents has ranged from $1.92 million in 2016 to $358.33 million in 2023, and is currently $344.87 million as of their latest financial filing in 2024.

How has Krystal Biotech's book value per share changed over the last 8 years?

Over the last 8 years, Krystal Biotech's book value per share changed from -1.27 in 2016 to 32.91 in 2024, a change of -2,685.1%.


Related Companies

This page (NASDAQ:KRYS) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored